Phase 1 first-in-human dose-expansion study of the oral SF3B1 modulator H3B‑8800 in lower-risk myelodysplastic syndrome. - Foran JM; Sanz GF; Watts JM; Brunner AM; Fossard G; Della Porta MG; Tsai XC; Garcia-Manero G; Dimicoli-Salazar S; Fletcher L; Kim YJ; Font P; et al. (Leukemia research, 2025)